Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

Study findings show that the standardized 6-month surveillance protocols for all patients with low-risk uveal melanoma may be ...

Blue-eyed people also have a higher risk of uveal (eye) melanoma, a rare cancer that affects about five in every million ...

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

No writing assistance was utilized in the production of this manuscript. Surgical management of uveal melanoma focuses on both the primary treatment of the tumor as well as treatment-related ...

HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit ...

You may have treatment with radiotherapy if you have melanoma of the eye (uveal melanoma). These treatments can work well, but some people have a small number of cancer cells left at the end of ...

Biallelic inactivation or deletion of BAP1 that is present in ~80% of metastatic uveal melanoma patients. We want to further understand the interplay of the liver microenvironment on uveal melanoma ...

Castle Biosciences, Inc. announced that it will present new research at the AACR Annual Meeting 2025 aimed at improving the care of patients with cutaneous and uveal melanoma. The presentations ...